We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
- Authors
Avet-Loiseau, Hervé; Leleu, Xavier; Roussel, Murielle; Moreau, Philippe; Guerin-Charbonnel, Catherine; Caillot, Denis; Marit, Gérald; Benboubker, Lotfi; Voillat, Laurent; Mathiot, Claire; Kolb, Brigitte; Macro, Margaret; Campion, Loïc; Wetterwald, Marc; Stoppa, Anne-Marie; Hulin, Cyrille; Facon, Thierry; Attal, Michel; Minvielle, Stéphane; Harousseau, Jean-Luc
- Abstract
Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 30, p4630
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.28.3945